Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Study Details
Study Description
Brief Summary
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
PRIMARY OBJECTIVE:
- To compare overall survival (OS) in participants previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC) randomized to pembrolizumab and ramucirumab versus standard of care.
SECONDARY OBJECTIVE:
- To summarize reports of serious and unexpected high-grade (>= grade 3) treatment-related adverse events determined by the treating physician within each treatment arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive chemotherapy per standard of care on study.
ARM B: Patients receive ramucirumab intravenously (IV) and pembrolizumab IV on study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: ARM A (standard of care chemotherapy) Patients receive chemotherapy per standard of care on study. |
Drug: Chemotherapy
Receive standard of care chemotherapy
Other Names:
|
| Experimental: ARM B (ramucirumab, pembrolizumab) Patients receive ramucirumab IV and pembrolizumab IV on study. |
Biological: Pembrolizumab
Given IV
Other Names:
Biological: Ramucirumab
Given IV
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall survival [From date of randomization to date of death due to any cause, assessed up to 3 years]
Assessed in participants with stage IV or recurrent non-small cell lung cancer with acquired resistance to anti-PD-1 or anti-PD-L1 therapy randomized to ramucirumab and pembrolizumab or standard of care chemotherapy. Will use an intention-to-treat analysis and the comparison will be done using a stratified log-rank test. The distribution of overall survival will be estimated using the method of Kaplan-Meier and a Cox proportional hazards model will be used to estimate hazard ratios and associated 95% confidence intervals to estimate treatment effects.
Secondary Outcome Measures
- Incidence of high-grade (>= grade 3) adverse events [Up to 3 years]
Unexpected treatment-related adverse events determined by the treating physician.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) which is stage IV or recurrent
-
Participants must have received at least one line of anti-PD-1 or anti-PD-L1 therapy for any stage of NSCLC. Anti-PD-1 or anti-PD-L1 may have been given alone or in combination with other therapy
-
Participants must have experienced disease progression (in the opinion of the treating physician) more than (>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 therapy
-
Participants who received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease, must have had a best response on anti-PD-1 or anti-PD-L1 therapy of stable, partial response or complete response (in the opinion of the treating physician)
-
Participants who received neoadjuvant, adjuvant, and/or consolidation anti-PD-1 or anti-PD-L1 therapy as their only line of anti-PD-1 or anti-PD-L1 therapy must have experienced disease progression within (=<) 365 days from initiation (cycle 1 day 1) of anti-PD-1 or PD-L1 therapy
-
Participants must have received platinum-based chemotherapy and experienced disease progression (in the opinion of the treating physician) during or after this regimen
-
Participants with a known sensitizing mutation for which an Food and Drug Administration (FDA)-approved targeted therapy for NSCLC exists (e.g., EGFR, ALK, ROS1, BRAF, RET, NTRK, KRAS, HER2 and MET sensitizing mutations), must have previously received at least one of the approved therapy(s). Prior targeted therapy for participants with targetable alterations is allowed if all other eligibility criteria are also met
-
Participants must be >= 18 years old
-
Participants must be able to safely receive the investigational drug combination and the investigator's choice of standard of care regimens per the current FDA approved package insert(s), treating investigator's discretion, and institutional guidelines
-
Participants must have Zubrod performance status of 0-2
Exclusion Criteria:
-
Participants must not have received more than one line of anti-PD-1 or anti-PD-L1 for stage IV or recurrent disease
-
Participants must not be receiving or planning to receive another investigational therapy during study participation
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Eli Lilly and Company
- Merck Sharp & Dohme LLC
Investigators
- Principal Investigator: Karen L Reckamp, Southwest Oncology Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- S2302
- NCI-2022-09319
- S2302
- S2302
- U10CA180888